Previous
Next
Discover VENCLEXTA® (venetoclax)
VENCLEXTA is a first-in-class selective inhibitor of BCL-2 that helps restore the process of apoptosis.1
PBS listed:
VENCLEXTA in combination with obinutuzumab is PBS listed as a first-line treatment for patients with CLL or SLL.2
VENCLEXTA in combination with rituximab is PBS listed for treatment of patients with relapsed or refractory CLL.2
VENCLEXTA in combination with azacitidine is PBS listed for treatment of adult patients with newly diagnosed AML ineligible for intensive chemotherapy.2
Visit www.pbs.gov.au for full criteria.
INDICATIONS
Acute Myeloid Leukaemia
VENCLEXTA, in combination with azacitidine or low-dose cytarabine, is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.1
Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
VENCLEXTA in combination with obinutuzumab is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who are considered unfit or unsuitable for chemo-immunotherapy.
VENCLEXTA in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
VENCLEXTA monotherapy is indicated for the treatment of:
- patients with relapsed or refractory CLL with 17p deletion, or
- patients with relapsed or refractory CLL for whom there are no other suitable treatment options.1
VIDEO & AUDIO RESOURCES
Data summarised by Professor Stephen Opat
Learn about the efficacy and safety findings for VENCLEXTA + obinutuzumab in 1L CLL from the phase 3 CLL14 study, as well as what this data means for Haematologists and their patients.
MURANO study: Key outcomes (R/R CLL) summarised by Professor John Seymour
Your guide to the efficacy and safety outcomes for VENCLEXTA + rituximab in R/R CLL from the phase 3 MURANO study, including the 5-year data.
CLL14 trial: Key outcomes (1L CLL) presented by Professor Barbara Eichhorst
Explore the efficacy and safety findings for VENCLEXTA + obinutuzumab in 1L CLL with coexisting medical conditions.
VENCLEXTA in AML
Your guide to initiating VENCLEXTA in combination with azacitidine in your patients with previously untreated AML.
Sequencing novel CLL treatments
Dr Mary-Ann Anderson examines different novel CLL treatments available in Australia and the data for sequencing VENCLEXTA from clinical trials and real-world experience.
Prof. Seymour interviews Prof. Kater on current CLL treatment landscape
Listen to audio of Professor J. Seymour interviewing Professor A. Kater about the current CLL treatment landscape.
7-year MURANO update with Prof. Kater
Watch Professor Arnon Kater discuss the 7-year follow-up analysis of the MURANO trial presented at EHA 2023.
6-year CLL14 update with Prof. Opat
Watch Professor Stephen Opat discuss the 6-year follow-up analysis of the CLL14 trial presented at EHA 2023.
Selecting a 1L CLL therapy with Prof. Opat
Listen as Prof. Stephen Opat (Monash Health) discusses the role of chemo-immunotherapy and when to use BKT inhibitors in 1L CLL.
SELF SERVICE
Visit our Nurse Resource Hub
Explore practical resources to support nurses in onboarding and managing CLL patients prescribed VENCLEXTA.
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
1L: first-line. AML: acute myeloid leukaemia. ASH: American Society of Hematology. ASO-PCR: allele-specific oligonucleotide polymerase chain reaction. AZA: azacitidine. Bcl-2: B-cell lymphoma 2. BR: bendamustine + rituximab. CI: confidence interval. CIT: chemoimmunotherapy. CLL: chronic lymphocytic leukaemia. Clb: chlorambucil. HR: hazard ratio. INV: investigator. ITT: intention-to-treat. MRD: minimal residual disease. O: obinutuzumab. OS: overall survival. PFS: progression-free survival. R: rituximab. R/R CLL: rela[sed or refractory CLL. SLL: small lymphocytic lymphoma. TLS: tumour lysis syndrome. 1L:: undetectable MRD. V: VENCLEXTA. VEN: VENCLEXTA.
References: 1. VENCLEXTA Product Information. 2. Australian Government Department of Health. Schedule of Pharmaceutical Benefits, www.pbs.gov.au Accessed August 2021.
AU-VENC-240047. Last revised October 2024